• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of child and adolescent psychopharmacology >Five-fold increase in national prevalence rates of attention-deficit/ hyperactivity disorder medications for children and adolescents with autism spectrum disorder, attention-deficit/hyperactivity disorder, and other psychiatric disorders: A danish register-based study
【24h】

Five-fold increase in national prevalence rates of attention-deficit/ hyperactivity disorder medications for children and adolescents with autism spectrum disorder, attention-deficit/hyperactivity disorder, and other psychiatric disorders: A danish register-based study

机译：针对患有自闭症谱系障碍，注意缺陷/多动障碍和其他精神疾病的儿童和青少年，注意力缺陷/多动障碍药物的全国患病率增加五倍：一项基于丹麦注册的研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: The purpose of this study was to estimate the prevalence and time trends in prescriptions of methylphenidate, dexamphetamine, and atomoxetine in children and adolescents, within three diagnostic groups: 1) autism spectrum disorder (ASD), 2) attention-deficit/hyperactivity disorder (ADHD), and 3) other psychiatric disorders. Methods: Data from six different national registers were used and merged to identify a cohort of all children and adolescents born in Denmark between 1990 and 2001 (n=852,711). Sociodemographic covariates on cohort members and their parents and lifetime prescriptions of methylphenidate, dexamphetamine, and atomoxetine were extracted from the registers. Prescriptions were also stratified by duration (<6 months. vs.≥6 months). Results: Sixteen percent of 9698 children and adolescents with ASD (n=1577), 61% of 11,553 children and adolescents with ADHD (n=7021) and 3% of 48,468 children and adolescents with other psychiatric disorders (n=1537) were treated with one or more ADHD medications. There was a significant increase in prescription rates of these medications for all three groups. From 2003 to 2010, youth 6-13 years of age with ASD, ADHD, and other psychiatric disorders had 4.7-fold (4.4-4.9), 6.3-fold (6.0-6.4), and 5.5-fold (5.0-5.9) increases, respectively, in prescription rates of ADHD medications. Conclusion: This is the largest study to date assessing stimulant treatment in children and adolescents with ASD, and is the first prospective study quantifying the change over time in the prevalence of treatment with ADHD medications in a population-based national cohort of children and adolescents with ASD. The prevalence of stimulant treatment in youth with ASD of 16% is consistent with earlier studies. The past decade has witnessed a clear and progressive increase in the prescription rates of medications typically used to treat ADHD in children and adolescents in Denmark. This increase is not limited to only those with ADHD, but includes others with neuropsychiatric disorders, including ASD. The risks and benefits of this practice await further study.
机译：目的：本研究的目的是评估三个诊断组中儿童和青少年的哌醋甲酯，右旋苯丙胺和阿托莫西汀处方的患病率和时间趋势：1）自闭症谱系障碍（ASD），2）注意缺陷/多动症障碍（ADHD），以及3）其他精神疾病。方法：使用来自六个不同国家注册簿的数据，并将其合并以识别1990年至2001年之间在丹麦出生的所有儿童和青少年的队列（n = 852,711）。从登记册中提取了该队列成员及其父母的社会人口统计学协变量，以及哌醋甲酯，右旋苯丙胺和阿托西汀的终生处方。处方也按疗程进行了分层（<6个月vs.≥6个月）。结果：9698名患有ASD的儿童和青少年（n = 1577）中有16％，11,553名患有ADHD的儿童和青少年中有61％（n = 7021）以及48,468名患有其他精神疾病的儿童和青少年中有3％（n = 1537）得到了治疗使用一种或多种ADHD药物。所有这三组的这些药物的处方率均显着增加。从2003年到2010年，患有ASD，ADHD和其他精神疾病的6-13岁青年分别增长4.7倍（4.4-4.9），6.3倍（6.0-6.4）和5.5倍（5.0-5.9）分别是ADHD药物的处方率。结论：这是迄今为止最大的评估ASD儿童和青少年兴奋剂治疗的研究，也是第一个量化以人群为基础的全国儿童和青少年ADHD药物治疗流行度随时间变化的前瞻性研究。 ASD。在ASD为16％的年轻人中，兴奋剂治疗的患病率与早期研究一致。在过去的十年中，丹麦儿童和青少年通常用于治疗多动症的药物的处方率出现了明显且逐步的增长。这种增加不仅限于患有ADHD的患者，还包括患有神经精神疾病的其他患者，包括ASD。这种做法的风险和收益有待进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号